NCT06161272 is a Phase 2 clinical trial of Fluzoparib in Ovarian Cancer, sponsored by Guangxi Medical University.

Who is sponsoring NCT06161272?

NCT06161272 is sponsored by Guangxi Medical University.

What drugs are being tested in NCT06161272?

Interventions in NCT06161272: Fluzoparib, Fluzoparib+Apatinib.

What condition does NCT06161272 study?

NCT06161272 studies Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer.

Is NCT06161272 still recruiting?

NCT06161272 is currently status unknown. Last updated 7 December 2023.

Last reviewed 2023-12-07 · How we verify

NCT06161272

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi

Status unknown Phase 2 Last updated 7 December 2023

What this trial tests

Phase 2 trial testing Fluzoparib in Ovarian Cancer in 80 participants. Status unknown.

Timeline

10 December 2023

Primary endpoint
10 March 2025

10 January 2026

Quick facts

Lead sponsor	Guangxi Medical University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	80
Start date	10 December 2023
Primary completion	10 March 2025
Estimated completion	10 January 2026
Sites	1 location across China

Drugs / interventions tested

Fluzoparib — full drug profile →
Fluzoparib+Apatinib

Conditions studied

Ovarian Cancer — all drugs for Ovarian Cancer →
High Grade Serous Adenocarcinoma of Ovary — all drugs for High Grade Serous Adenocarcinoma of Ovary →
Primary Peritoneal Carcinoma — all drugs for Primary Peritoneal Carcinoma →
Fallopian Tube Cancer — all drugs for Fallopian Tube Cancer →

Sponsor

Guangxi Medical University

Who can join

Adults 18 to 75, female only, with Ovarian Cancer or High Grade Serous Adenocarcinoma of Ovary. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized, multicenter, two-arm, noncomparative, phase II study of fluzoparib with or without apatinib for maintenance therapy in PARPi-pretreated platinum-sensitive recurrent ovarian cancer. The primary objective is to evaluate median progression free survival of fluzoparib with or without apatinib.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Fluzoparib

Trials testing the same drug.

NCT07353437 — Fluzoparib as Adjuvant Treatment in Patients With Germline Homologous Recombination Repair (HRR) Mutated Primary Breast · Phase 2 · not yet recruiting
NCT07382713 — Fluzoparib Plus Famitinib Maintenance After First-Line Platinum Response in Advanced Ovarian Cancer · Phase 2 · not yet recruiting
NCT07141771 — An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing · Phase 1, PHASE2 · not yet recruiting
NCT06735326 — Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer · Phase 2 · recruiting
NCT06539091 — Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer · Phase 3 · not yet recruiting

Other recruiting trials for Ovarian Cancer

Currently open trials in the same condition.

NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other Guangxi Medical University trials

Trials by the same sponsor.

NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT06851104 — A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of Recurrence · Phase 2 · terminated
NCT05711823 — Aprepitant Plus Granisetron and Dexamethasone for the Prevention of Vomiting in Patients With HAIC Therapy for HCC · Phase 3 · unknown
NCT05910970 — Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation · Phase 3 · unknown
NCT05898256 — Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06161272 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guangxi Medical University
Last refreshed: 7 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06161272.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing